Jiangsu Hengrui Pharmaceuticals (01276): HRS-4139 Tablets Receive Drug Clinical Trial Approval Notice

Jiangsu Hengrui Pharmaceuticals (01276) announced that recently, Fujian Shengdi Pharmaceutical Co., Ltd., a subsidiary of Jiangsu Hengrui Pharmaceuticals Co., Ltd. (hereinafter referred to as the "Company"), received the Drug Clinical Trial Approval Notice for HRS-4139 Tablets approved and issued by the National Medical Products Administration (hereinafter referred to as the "NMPA"), and will soon initiate clinical trials. HRS-4139 Tablets are a Class 1 new drug independently developed by the Company. In animal models, it can effectively improve psoriasis symptoms and inhibit inflammatory responses. Upon review, no drugs targeting the same target have been approved for marketing domestically or internationally. As of now, the cumulative R&D investment in HRS-4139 Tablets-related projects is approximately RMB 20.4 million (unaudited).